

Thursday, January 25, 2001

Dr. Scott Masten
NIEHS/NTP
111 TW Alexander Dr
Bldg 101 Room B316
Research Triangle Park, NC 27709

Recul 1/2401 indéx n/athebut co-Rom Submitted mrospage to 12/4/00 FRAW 12e

Dear Dr. Masten.

I had previously tried to email you this information from my work email but because of the large attached file our corporate firewall wouldn't allow it. I had spoken with you in mid December regarding S-adenosylmethionine (SAMe). BASF Corporation and our German Parent Company BASF AG are a large producer of this product and we have performed numerous studies on the material.

I have enclosed the FDA 75 Premarket notification (publicly available from the FDA under FOI) that was filed by one of our US customers. This document details many of the safety and other studies performed on SAMe by BASF Corporation and other researchers. I have attached this document in case you haven't seen this. Although this information is publicly available, you most likely would not have found this data during a routine literature search. It also references some BASF proprietary studies not publicly available.

My German and Italian Colleagues would be very interested in discussing the safety of this product with you and providing any additional information that they may have. Also, they would be interested in discussing providing you with test material at no charge should you go forward with your planned studies.

BASF has a strong commitment to only marketing products for which we have adequately demonstrated safety. I trust you will find the enclosed information very extensive and complete. If you would like me to arrange further contact with our technical experts in Germany or Italy please let me know.

Thank you for your time.

Sincerely Yours.

Wendy Mavroudakis
Manager, Regulatory Affairs

**BASF Corporation** 

973-426-4728

Email address: mavrouw@basf.com